WANY
CORT icon

Wealthspire Advisors (New York)’s Corcept Therapeutics CORT Stock Holding History

Wealthspire Advisors (New York)’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$308K Buy
+3,540
New +$214K ﹤0.01% 983
2025
Q4 		– Sell
-3,864
Closed -$321K – 1410
2025
Q3 		$321K Sell
3,864
-102
-3% -$7.38K ﹤0.01% 639
2025
Q2 		$291K Sell
3,966
-47
-1% -$3.41K ﹤0.01% 677
2025
Q1 		$458K Buy
+4,013
New +$244K ﹤0.01% 532

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wealthspire Advisors (New York)'s CORT Position: Q2 2026 in Review

Wealthspire Advisors (New York) opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 3,540 shares worth $308K. The stake represents ﹤0.01% of the portfolio and ranks #983 among its holdings. This is a return to the name: Wealthspire Advisors (New York) previously reported a position in CORT as recently as Q3 2025.

Wealthspire Advisors (New York) first reported a position in CORT in Q1 2025 and has held it in 4 quarters since. The position peaked at $458K in Q1 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Wealthspire Advisors (New York) held 3,540 shares of Corcept Therapeutics worth $308K as of Q2 2026.
  • Corcept Therapeutics was a new Wealthspire Advisors (New York) position in Q2 2026.
  • Corcept Therapeutics made up ﹤0.01% of Wealthspire Advisors (New York)'s portfolio in Q2 2026, its #983 holding.
  • Wealthspire Advisors (New York) first reported a position in Corcept Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • Wealthspire Advisors (New York)'s Corcept Therapeutics position peaked at $458K in Q1 2025.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Wealthspire Advisors (New York)'s 13F filing for Q2 2026, filed 11 Aug 2026.